Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2005

View Archived Issues

Minocycline decreases the need for oral steroids in adult patients with asthma

Preclinical data support development of lisofylline as a treatment for type 1 diabetes

PDE3 inhibitor shows potential clinical use as a contraceptive / News in Context

ACE BioSciences and SynCo collaborate on GMP production of ACE-393

LT-1951 enters phase I/IIa for prevention of CABG failure

FDA approves amendments to Corautus Genetics' GENASIS gene therapy trial

Preclinical study findings for Alltracel's m.doc technology platform

Colombian approval for Impavido for cutaneous leishmaniasis

BioWa licenses anti-IL-5 receptor antibody from Kyowa Hakko Kogyo

Immunization studies reveal a novel human asthma vaccine

SGS-742 evaluated in new phase II study for adult ADHD

Leukolysin: a new target for asthma

Completion of enrollment for phase I HIV vaccine trial

The PARP inhibitor INO-1001 does not affect DNA repair and cell senescence

Ventavis now available for PAH

NIM-811 as a treatment for apoptosis and myocardial mitochondrial dysfunction in sepsis

Aphton shareholders approve Igeneon acquisition

NX-1207 shows promise for BPH

U.K. clearance for phase III study of COLAL-PRED for acute ulcerative colitis

Cerepro progresses in Europe

Regulatory pathway considered for Vitor in Europe

Solvay to acquire Fournier Pharma

Cannabinoid CB1 antagonists active in advanced Parkinson's disease model

Rosiglitazone protects against experimental acute lung injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...